Max Planck spin-off takes the next step from lab to biopharma and nutrition markets for activated sugars and glycans.

Biotech start-up eversyn GmbH has been awarded €180,000 in Phase II funding from EXIST Transfer of Research, the German federal programme for research-based spin-offs. Together with €920,000 from Phase I, eversyn’s EXIST support now totals €1.1 million. The funding has taken the company from a research project at the Max Planck Institute in Magdeburg to an independent business.

eversyn produces nucleotide sugars and glycans, the sugar building blocks behind many biological processes. Researchers in pharma and nutrition rely on them, yet until now only a handful of suppliers worldwide have offered them. eversyn makes them using a patented cell-free process built on more than a decade of research.

Phase I funded the move from lab to company: building the team, developing the product range and introducing the first products to pilot customers. Phase II goes directly to the newly founded eversyn GmbH. It supports the company’s next stage as it brings its products to market at scale and prepares for external investment.

“When we started, we had a technology with years of research behind it and one big question: Could it move beyond the research institute and make a difference in people’s lives? EXIST gave us the room to answer it” – said Rachel Thu Nguyen, Co-Founder and Chief Business Officer of eversyn. “Phase II helps us build on the trust our pilot customers have placed in us and take the next step.”

EXIST is funded by the German Federal Ministry for Economic Affairs and Climate Action (BMWK) and co-financed by the European Social Fund Plus (ESF Plus).
‍
About eversyn
‍eversyn GmbH is a biotech company based in Magdeburg, Germany, and a spin-off of the Max Planck Society. Using its patented cell-free biosynthesis platform, eversyn produces nucleotide sugars and glycans for research and development in pharma, diagnostics and nutrition. www.eversyn.de
‍
Media contact
‍Rachel Thu Nguyen
Co-Founder and Chief Business Officer
Email: rachel.nguyen@eversyn.de